Skip to main content

Advertisement

SpringerLink
Log in

Expansion of the CRISPR/Cas Genome-Sculpting Toolbox: Innovations, Applications and Challenges

  • Review Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

The emergence of the versatile gene-editing technology using programmable sequence-specific endonuclease system (CRISPR-Cas9) has instigated a major upheaval in biomedical research. In a brief span of time, CRISPR/Cas has been adopted by research labs around the globe because of its potential for significant progress and applicability in terms of efficiency, versatility and simplicity. It is a breakthrough technique for systematic genetic engineering, genome labelling, epigenetic and transcriptional modulation, and multiplexed gene editing, amongst others. This review provides an illustrative overview of the current research trends using CRISPR/Cas technology. We highlight the latest developments in CRISPR/Cas technique including CRISPR imaging, discovery of novel CRISPR systems, and applications in altering the genome, epigenome or RNA in different organisms. Finally, we address the potential challenges of this technique for its future use.

Graphic Abstract

Development of new CRISPR/Cas systems

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol. 2016;34:933–41.

    CAS  PubMed  Google Scholar 

  2. Sorek R, Lawrence CM, Wiedenheft B. CRISPR-mediated adaptive immune systems in bacteria and archaea. Annu Rev Biochem. 2013;82:237–66.

    CAS  PubMed  Google Scholar 

  3. Jao LE, Wente SR, Chen W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc Natl Acad Sci USA. 2013;110:13904–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JW, Xi JJ. Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos. Cell Res. 2013;23:465–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Gratz SJ, Rubinstein CD, Harrison MM, Wildonger J, O’Connor-Giles KM (2015) CRISPR-Cas9 genome editing in Drosophila. Curr Protoc Mol Biol. 2015:31.2.1–31.2.20.

  6. Bassett AR, Kong L, Liu JL. A genome-wide CRISPR Library For High-Throughput Genetic Screening In Drosophila Cells. J Genet Genom. 2015;42:301–9.

    CAS  Google Scholar 

  7. Ma S, Chang J, Wang X, Liu Y, Zhang J, Lu W, Gao J, Shi R, Zhao P, Xia Q. CRISPR/Cas9 mediated multiplex genome editing and heritable mutagenesis of BmKu70 in Bombyx mori. Sci Rep. 2014;4:1–6.

    Google Scholar 

  8. Dickinson DJ, Ward JD, Reiner DJ, Goldstein B. Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nat Methods. 2013;10:1028–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Li D, Qiu Z, Shao Y, et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol. 2013;31:681–3.

    CAS  PubMed  Google Scholar 

  10. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, Yan Z, Li D, Li J. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell. 2013;13:659–62.

    CAS  PubMed  Google Scholar 

  11. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013;31:833–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakatura A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isoenzyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Mojica FJM, Díez-Villaseñor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol Microbiol. 2000;36:244–6.

    CAS  PubMed  Google Scholar 

  14. Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct. 2006;1:1–26.

    Google Scholar 

  15. Barrangou Rodolphe, Fremaux Christophe, Deveau Hélène, Richards Melissa, Boyaval Patrick, Moineau Sylvain, Romero Dennis A, Horvath Philippe. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007. https://doi.org/10.1126/science.1136466.

    Article  PubMed  Google Scholar 

  16. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA—guided. Science. 2012;337:816–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Westra ER, Semenova E, Datsenko KA, Jackson RN, Wiedenheft B, Severinov K, Brouns SJJ. Type I-E CRISPR-Cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition. PLoS Genet. 2013. https://doi.org/10.1371/journal.pgen.1003742.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Makarova KS, Wolf YI, Alkhnbashi OS, et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015;13:722–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Makarova KS, Wolf YI, Iranzo J, et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18:67–83.

    CAS  PubMed  Google Scholar 

  21. Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, Doudna JA. Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity. Nat Struct Mol Biol. 2014;21:528–34.

    PubMed  PubMed Central  Google Scholar 

  22. Xiao Y, Ng S, Hyun Nam K, Ke A. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration. Nature. 2017;550:137–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. He L, St. John James M, Radovcic M, Ivancic-bace I, Bolt EL. Cas3 protein—a review of a multi-tasking machine. Genes (Basel) 2020;11(2):208.

    CAS  Google Scholar 

  24. Dolan AE, Hou Z, Xiao Y, Gramelspacher MJ, Heo J, Howden SE, Freddolino PL, Ke A, Zhang Y. Introducing a spectrum of long-range genomic deletions in human embryonic stem cells using type I CRISPR-Cas. Mol Cell. 2019;74:936–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Lee H, Dhingra Y, Sashital DG (2019) The Cas4-Cas1-Cas2 complex mediates precise prespacer processing during CRISPR adaptation. eLife 8:1–26.

  26. Zhang Z, Pan S, Liu T, Li Y, Peng N. Cas4 nucleases can effect specific integration of CRISPR spacers. J Bacteriol. 2019. https://doi.org/10.1128/JB.00747-18.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Carte J, Wang R, Li H, Terns RM, Terns MP. Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev. 2008;22:3489–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Brendel J, Stoll B, Lange SJ, et al. A complex of cas proteins 5, 6, and 7 is required for the biogenesis and stability of clustered regularly interspaced short palindromic repeats (CRISPR)-derived RNAs (crRNAs) in haloferax volcanii. J Biol Chem. 2014;289:7164–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Hrle A, Su AAH, Ebert J, Benda C, Randau L, Conti E. Structure and RNA-binding properties of the type III-A CRISPR-associated protein Csm3. RNA Biol. 2013;10:1670–8.

    PubMed  PubMed Central  Google Scholar 

  30. Kalwani P, Rath D, Ballal A. Novel molecular aspects of the CRISPR backbone protein “Cas7” from cyanobacteria. Biochem J. 2020;477:971–83.

    CAS  PubMed  Google Scholar 

  31. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, Ishitani R, Zhang F, Nureki O. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014;156:935–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Brezgin S, Kostyusheva A, Kostyushev D, Chulanov V. Dead cas systems: types, principles, and applications. Int J Mol Sci. 2019;20:1–26.

    Google Scholar 

  33. Ran FA, Hsu PD, Lin CY, et al. Erratum: double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity (Cell (2013) 154 (1380-1389)). Cell. 2013;155:479–80.

    CAS  Google Scholar 

  34. Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol. 2015;11:198–200.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Nihongaki Y, Kawano F, Nakajima T, Sato M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol. 2015;33:755–60.

    CAS  PubMed  Google Scholar 

  36. Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A. Optical control of CRISPR/Cas9 gene editing. J Am Chem Soc. 2015;137:5642–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Rojas-Fernandez A, Herhaus L, Macartney T, Lachaud C, Hay RT, Sapkota GP. Rapid generation of endogenously driven transcriptional reporters in cells through CRISPR/Cas9. Sci Rep. 2015;5:1–6.

    Google Scholar 

  38. Ratz M, Testa I, Hell SW, Jakobs S. CRISPR/Cas9-mediated endogenous protein tagging for RESOLFT super-resolution microscopy of living human cells. Sci Rep. 2015;5:1–6.

    Google Scholar 

  39. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435:646–51.

    CAS  PubMed  Google Scholar 

  40. Bedell VM, Wang Y, Campbell JM, et al. In vivo genome editing using a high-efficiency TALEN system. Nature. 2012;491:114–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397–405.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Doyle EL, Booher NJ, Standage DS, Voytas DF, Brendel VP, Vandyk JK, Bogdanove AJ. TAL effector-nucleotide targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. 2012;40:117–22.

    Google Scholar 

  43. Hsu PD, Scott DA, Weinstein JA, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31:827–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31:822–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Lin S, Staahl BT, Alla RK, Doudna JA (2014) Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3:e04766.

  46. Levy A, Goren MG, Yosef I, Auster O, Manor M, Amitai G, Edgar R, Qimron U, Sorek R. CRISPR adaptation biases explain preference for acquisition of foreign DNA. Nature. 2015;520:505–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol. 2015;33:102–6.

    CAS  PubMed  Google Scholar 

  48. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang Y, Wang B, Xie H, et al. Efficient Human genome editing using SaCas9 ribonucleoprotein complexes. Biotechnol J. 2019;14:1–8.

    Google Scholar 

  50. Schunder E, Rydzewski K, Grunow R, Heuner K. First indication for a functional CRISPR/Cas system in Francisella tularensis. Int J Med Microbiol. 2013;303:51–60.

    CAS  PubMed  Google Scholar 

  51. Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a Class 2 CRISPR-Cas system. Cell. 2015;163:759–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw ZR, Aryee MJ, Joung JK. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol. 2016;34:869–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Kim HK, Song M, Lee J, et al. In vivo high-throughput profiling of CRISPR-Cpf1 activity. Nat Methods. 2017;14:153–9.

    CAS  PubMed  Google Scholar 

  54. Fonfara I, Richter H, BratoviÄ M, le Rhun A, Charpentier E. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature. 2016;532:517–21.

    CAS  PubMed  Google Scholar 

  55. Moreno-Mateos MA, Fernandez JP, Rouet R, Vejnar CE, Lane MA, Mis E, Khokha MK, Doudna JA, Giraldez AJ. CRISPR-Cpf1 mediates efficient homology-directed repair and temperature-controlled genome editing. Nat Commun. 2017;8:1–9.

    CAS  Google Scholar 

  56. Shmakov S, Abudayyeh OO, Makarova KS, et al. Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell. 2015;60:385–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Burstein D, Harrington LB, Strutt SC, Probst AJ, Anantharaman K, Thomas BC, Doudna JA, Banfield JF. New CRISPR-Cas systems from uncultivated microbes. Nature. 2017;542:237–41.

    CAS  PubMed  Google Scholar 

  58. Harrington LB, Harrington LB, Burstein D, et al. Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science. 2018;4294:1–8.

    Google Scholar 

  59. Liu JJ, Orlova N, Oakes BL, et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature. 2019;566:218–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, Scott DA. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell. 2018;70:327–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Smargon AA, Cox DBT, Pyzocha NK, et al. Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28. Mol Cell. 2017;65:618–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173:665–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Aquino-Jarquin G. CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic. Nanomed Nanotechnol Biol Med. 2019;18:428–31.

    CAS  Google Scholar 

  64. Rath D, Amlinger L, Hoekzema M, Devulapally PR. Efficient programmable gene silencing by Cascade. Cascade. 2015;43:237–46.

    CAS  Google Scholar 

  65. Strecker J, Ladha A, Gardner Z, Schmid-Burgk JL, Makarova KS, Koonin EV, Zhang F. RNA-guided DNA insertion with CRISPR-associated transposases. Science. 2019;365(6448):48–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Klompe SE, Vo PLH, Halpin-healy TS, Sternberg SH. Article Transposon-encoded CRISPR—Cas systems. Nature. https://doi.org/10.1038/s41586-019-1323-z.

  67. Chen B, Gilbert LA, Cimini BA, et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell. 2013;155:1479–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-γuided platform for sequence-specific control of gene expression. Cell. 2013;152:1173–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Gilbert LA, Larson MH, Morsut L, et al. XCRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154:442.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Sánchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 2015;15:387–95.

    PubMed  PubMed Central  Google Scholar 

  71. Choi PS, Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014;5:1–6.

    CAS  Google Scholar 

  72. Gerace D, Martiniello-Wilks R, Nassif NT, Lal S, Steptoe R, Simpson AM. CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? Stem Cell Res Ther. 2017;8:1–10.

    Google Scholar 

  73. Chung JY, Ul Ain Q, Song Y, Yong SB, Kim YH. Targeted delivery of CRISPR interference system against Fabp4 to white adipocytes ameliorates obesity, inflammation, hepatic steatosis, and insulin resistance. Genome Res. 2019;29:1442–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Hammond A, Galizi R, Kyrou K, et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol. 2016;34:78–83.

    CAS  PubMed  Google Scholar 

  75. Alphey L. Can CRISPR-Cas9 gene drives curb malaria? Nat Biotechnol. 2016;34:149–50.

    CAS  PubMed  Google Scholar 

  76. Dong Y, Simões ML, Marois E, Dimopoulos G. CRISPR/Cas9-mediated gene knockout of Anopheles gambiae FREP1 suppresses malaria parasite infection. PLoS Pathog. 2018;14:1–16.

    Google Scholar 

  77. Adelman ZN, Tu Z. Control of mosquito-borne infectious diseases: sex and gene drive. Trends Parasitol. 2016;32:219–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Yu Vionnie W C, PhD Yi Liu, PhD Matthew Curran, Pu Zhang MD, Jennifer Snead PhD, Schmedt Christian, Yi Yang PhD, Lin Victor Guosheng, Tschantz William R, PhD Lisa Quinn, Russ Carsten, Clarkson Scott, Janiak Amy, Morag Stewart PhD, Yanick Mulumba SS. CRISPR/Cas9 gene-edited hematopoietic stem cell therapy for sickle cell disease. Blood. 2017;130:535.

    Google Scholar 

  79. Park So Hyun, Lee Ciaran M, Deshmukh Harshavardhan, Gang Bao P. Therapeutic Crispr/Cas9 genome editing for treating sickle cell disease. Blood. 2016;128:4703.

    Google Scholar 

  80. Ye L, Wang J, Tan Y, Beyer AI, Xie F, Muench MO, Kan YW. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: an approach for treating sickle cell disease and β-thalassemia. Proc Natl Acad Sci USA. 2016;113:10661–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause duchenne muscular dystrophy. Nat Commun. 2015;6:1–13.

    Google Scholar 

  82. Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8:1–9.

    Google Scholar 

  83. Long C, Long C, Amoasii L, et al (2015) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 5725.

  84. Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science (New York, NY). 2015;5177:1–9.

    Google Scholar 

  85. Li HL, Fujimoto N, Sasakawa N, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep. 2015;4:143–54.

    CAS  Google Scholar 

  86. Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653–8.

    CAS  PubMed  Google Scholar 

  87. Crane AM, Kramer P, Bui JH, et al. Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Rep. 2015;4:569–77.

    CAS  Google Scholar 

  88. Maule G, Casini A, Montagna C, Ramalho AS, de Boeck K, Debyser Z, Carlon MS, Petris G, Cereseto A. Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing. Nat Commun. 2019. https://doi.org/10.1038/s41467-019-11454-9.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA. 2014;111:11461–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas based antiviral strategies against HIV-1. Virus Res. 2018;244:321–32.

    CAS  PubMed  Google Scholar 

  91. Bella R, Kaminski R, Mancuso P, et al. Removal of HIV DNA by CRISPR from patient blood engrafts in humanized mice. Mol Ther Nucleic Acids. 2018;12:275–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. van Diemen FR, Kruse EM, Hooykaas MJG, Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJHJ, Lebbink RJ. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog. 2016;12:1–29.

    Google Scholar 

  93. Roehm PC, Shekarabi M, Wollebo HS, Bellizzi A, He L, Salkind J, Khalili K. Inhibition of HSV-1 replication by gene editing strategy. Sci Rep. 2016;6:1–11.

    Google Scholar 

  94. Donohoue PD, Barrangou R, May AP. Advances in industrial biotechnology using CRISPR-Cas systems. Trends Biotechnol. 2018;36:134–46.

    CAS  PubMed  Google Scholar 

  95. Schwartz CM, Hussain MS, Blenner M, Wheeldon I. Synthetic RNA polymerase III promoters facilitate high-efficiency CRISPR-Cas9-mediated genome editing in yarrowia lipolytica. ACS Syn Biol. 2016;5:356–9.

    CAS  Google Scholar 

  96. Wang Y, Cheng X, Shan Q, Zhang Y, Liu J, Gao C, Qiu JL. Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew. Nat Biotechnol. 2014;32:947–51.

    CAS  PubMed  Google Scholar 

  97. Montenegro M (2016) CRISPR is coming to agriculture—with big implications for food, farmers, consumers and nature. Ensia 1–15.

  98. Carlson DF, Lancto CA, Zang B, Kim ES, Walton M, Oldeschulte D, Seabury C, Sonstegard TS, Fahrenkrug SC. Production of hornless dairy cattle from genome-edited cell lines. Nat Biotechnol. 2016;34:479–81.

    CAS  PubMed  Google Scholar 

  99. Waltz E. Gene-edited CRISPR mushroom escapes US regulation. Nature. 2016;532:293.

    CAS  PubMed  Google Scholar 

  100. Esvelt KM, Smidler AL, Catteruccia F, Church GM (2014) Concerning RNA-guided gene drives for the alteration of wild populations. eLife 3:1–21.

  101. Reardon S. The crispr zoo. Nature. 2016;531:160–3.

    CAS  PubMed  Google Scholar 

  102. Hwang WY, Fu Y, Reyon D, Maeder ML, Kaini P, Sander JD, Joung JK, Peterson RT, Yeh JRJ. Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS ONE. 2013;8:1–9.

    Google Scholar 

  103. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. XOne-step generation of mice carrying reporter and conditional alleles by CRISPR/cas-mediated genome engineering. Cell. 2013;154:1370.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Bohannon J. Biologists devise invasion plan for mutations. Science. 2014;347(6228):1300.

    CAS  PubMed  Google Scholar 

  105. Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6:363–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. On human gene editing: international summit statement. The National Academies of Sciences. 2015. http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=12032015a. Accessed 3 Dec 2015.

  107. International Summit on Human Gene Editing. The National Academies of Sciences, Engineering, and Medicine. http://nationalacademies.org/gene-editing/Gene-Edit-Summit/. Accessed Dec 2015.

  108. On Human Genome Editing II, Statement by the Organizing Committee of the Second International Summit on Human Genome Editing. In: The National Academies of Sciences, Engineering, and Medicine. 2018. http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=11282018b. Accessed 28 Nov 2018.

  109. Mo O. CRISPR-Cas9 human genome editing: challenges, ethical concerns and implications. J Clin Res Bioethics. 2015;06:5–7.

    Google Scholar 

  110. Garrity C. CRISPR mechanism. Medford: Tufts University; 2014.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Branch Srinagar, Jammu, J&K, 190005, India

    Asiya Batool & Fayaz Malik

  2. Department of Biotechnology, Science Block, University of Kashmir, Hazratbal, Srinagar, J&K, 190006, India

    Asiya Batool & Khurshid Iqbal Andrabi

Authors
  1. Asiya Batool
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fayaz Malik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Khurshid Iqbal Andrabi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asiya Batool.

Ethics declarations

Funding

Financial support in favour of Asiya Batool from the DBT-RA Program in Biotechnology and Life Sciences is gratefully acknowledged.

Conflicts of interest/competing interests

The authors confirm that they do not have any financial or non-financial competing interest in the publication of this paper.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Batool, A., Malik, F. & Andrabi, K.I. Expansion of the CRISPR/Cas Genome-Sculpting Toolbox: Innovations, Applications and Challenges. Mol Diagn Ther 25, 41–57 (2021). https://doi.org/10.1007/s40291-020-00500-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-020-00500-8

Search

Navigation